Fibroblast activation protein-targeting car t-cell, preparation method therefor, and application thereof

By targeting CAR-T cells with fibroblast activation proteins, chimeric antigen receptors and single-chain antibody fragments are used to achieve specific recognition and clearance of FAP, overcoming the shortcomings of existing technologies in targeting and clearing FAP cells, and providing a new treatment method for a variety of diseases.

WO2026144067A1PCT designated stage Publication Date: 2026-07-09GUANGZHOU ANJIE BIOMEDICAL TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
GUANGZHOU ANJIE BIOMEDICAL TECH CO LTD
Filing Date
2025-06-30
Publication Date
2026-07-09

AI Technical Summary

Technical Problem

Current CAR-T cell therapies are insufficient in targeting and eliminating cells expressing fibroblast activator protein (FAP), making it difficult to achieve specific recognition and effective elimination, thus affecting the treatment efficacy of various diseases.

Method used

T cells modified with chimeric antigen receptor (CAR) can specifically recognize FAP through a single-chain antibody fragment (scFv), activate intracellular signaling pathways, release the cytokine IFN-γ, exhibit cytotoxic effects, and clear FAP+ cells.

Benefits of technology

It achieves specific clearance of FAP+ cells, providing a new treatment strategy for a variety of diseases such as fibrosis, arthritis, autoimmune diseases and cardiovascular diseases, and has broad application potential and commercial value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2025105897_09072026_PF_FP_ABST
    Figure CN2025105897_09072026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the field of cell therapy. Disclosed are a fibroblast activation protein-targeting CAR T-cell, a preparation method therefor, and an application thereof. A CAR T-cell can be prepared by introducing an FAP-targeting chimeric antigen receptor (CAR) into a T lymphocyte, wherein the CAR in the CAR T-cell comprises a signal peptide, an antigen-binding domain, a hinge region, a transmembrane domain, a co-stimulatory signaling region, and a CD3 signaling domain. The CAR T-cell specifically recognizes the FAP by means of a single-chain variable fragment (scFv), which activates an intracellular signaling pathway, releasing cytokine IFN-γ, and exhibiting a cytotoxic effect on FAP+ cells, thereby achieving specific depletion of FAP+ cells at a lesion site. The CAR-T cell can be used for treating diseases characterized by upregulated FAP expression, such as fibrosis (pulmonary fibrosis, hepatic fibrosis, cardiac fibrosis, renal fibrosis, etc.), arthritis, autoimmune disorders (Crohn's disease, rheumatoid arthritis, etc.), and cardiovascular diseases, and demonstrates tremendous application potential and commercial value.
Need to check novelty before this filing date? Find Prior Art